Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI).
METHODS: We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S).
RESULTS: We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178).
CONCLUSIONS: Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 Suppl 1 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 113 Suppl 1(2021) vom: 01. Dez., Seite S82-S87 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petrone, Linda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.12.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.02.090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322706327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322706327 | ||
| 003 | DE-627 | ||
| 005 | 20231225182616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.02.090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1075.xml |
| 035 | |a (DE-627)NLM322706327 | ||
| 035 | |a (NLM)33713816 | ||
| 035 | |a (PII)S1201-9712(21)00176-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petrone, Linda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI) | ||
| 520 | |a METHODS: We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S) | ||
| 520 | |a RESULTS: We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178) | ||
| 520 | |a CONCLUSIONS: Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Co-infection | |
| 650 | 4 | |a IFN-gamma response | |
| 650 | 4 | |a M. tuberculosis | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 4 | |a Whole blood assay | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a IFNG protein, human |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 700 | 1 | |a Petruccioli, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Vanini, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Cuzzi, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Gualano, Gina |e verfasserin |4 aut | |
| 700 | 1 | |a Vittozzi, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Maffongelli, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Grifoni, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Sette, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Migliori, Giovanni Battista |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 113 Suppl 1(2021) vom: 01. Dez., Seite S82-S87 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:113 Suppl 1 |g year:2021 |g day:01 |g month:12 |g pages:S82-S87 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.02.090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 Suppl 1 |j 2021 |b 01 |c 12 |h S82-S87 | ||